MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    Smartphone-based digital assessments in the LUMA trial of BIIB122 for early-stage Parkinson’s disease

    R. Llorens Arenas, J. Edgerton, E. Bartholomé, S. Belachew, M. Gifford, J. Guo, B. Hersh, D. Jennings, C. Kanzler, E. Koca, M. Pang, O. Reyes, C. Shen, M. Wald, N. Woody, C. Mazzá (Cambridge, USA)

    Objective: To evaluate the sensitivity of routine smartphone-based performance assessments in the free-living environment as part of a randomized clinical trial in Parkinson’s disease (PD).…
  • 2025 International Congress

    Evaluation of Impact of Helicobacter Pylori Eradication on Symptomatology and Quality of Life in Parkinson’s Disease

    A. Kakkar, G. Vishwas, S. Mehta, S. Pattanaik, S. Bhattacharyya, V. Sharma, M. Modi (Chandigarh, India)

    Objective: This study aimed to determine the effects of Helicobacter Pylori(HP) eradication treatment on motor and non-motor symptoms and quality of life of PD patients…
  • 2025 International Congress

    Quality of Life Improvements in Parkinson’s Disease for Those Treated with Photobiomodulation Plus Exercise: A Sham-Controlled Study

    A. Saltmarche, O. Hares, A. Liebert, B. Bicknell, M. Naeser, G. Heller, J. Sykes, K. Togeretz, A. Namini, G. Herkes (Toronto, Canada)

    Objective: To assess whether exercise alone, or exercise combined with photobiomodulation (PBM) can improve the health-related quality of life (QoL) for people with Parkinson’s disease…
  • 2025 International Congress

    Random-Order Crossover Trial Assessing the Safety, Feasibility and Exploratory Efficacy of Two Mediterranean-Ketogenic Nutritional Interventions in Parkinson’s Disease

    K. Tosefsky, J. Lam, Y. Wang, A. Kuan, S. Appel-Cresswell (Vancouver, Canada)

    Objective: Assess the feasibility, safety and exploratory efficacy of two Mediterranean-ketogenic dietary interventions in individuals with Parkinson’s disease (PD). Background: Both Mediterranean and ketogenic diets…
  • 2025 International Congress

    A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the NLRP3 Inhibitor Vent-02 in Patients with Mild to Moderate Parkinson’s Disease

    A. Matta, X. Valencia, K. Pike, L. Warner, O. Spiegelstein, M. Bigal (Waltham, USA)

    Objective: To describe the innovative Phase 2 study design aimed to investigate vent-02 in the treatment of PD. Background: NLRP3 hyperactivation plays a critical role…
  • 2025 International Congress

    Ferritin-related Brain Iron Deposition in Parkinson’s Disease Involves α-Synuclein Pathology

    L. Luo, D. Su, Z. Yu, T. Feng (Beijing, China)

    Objective: To investigate plasma neuron-derived ferritin-containing extracellular vesicles (NDFEVs) differences between Parkinson’s disease (PD) patients and controls, assess their association with brain iron deposition, and explore the…
  • 2025 International Congress

    The neuroprotective effects of Echinacoside on α-synuclein fibril-induced Parkinson’s disease mice model

    Q. Zhao, S. Bu, Z. Wang, L. Jin (Shanghai, China)

    Objective: This study further investigates the ameliorative effects of ECH on neurobehavioral abnormalities and nigrostriatal dopaminergic system impairment in α-synuclein preformed fibrils (α-Syn PFFs)-induced PD…
  • 2025 International Congress

    Gastrointestinal Dysfunction and Levodopa Therapeutic Response in Parkinson’s Disease: A Brazilian Cross-sectional Study

    N. Dos Santos, G. de Vasconcelos, G. Piñeiro, F. Brito, J. Oliveira, S. Baran, J. Costa, E. Muricy, R. Kauark (Salvador, Brazil)

    Objective: To investigate the relation between constipation and the onset time of levodopa therapeutic effect in Parkinson's disease (PD). Background: Levodopa therapeutic response depends on…
  • 2025 International Congress

    COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Three Months Analysis Of REONPARK Study

    L. López-Manzanares, M. Cerdán Sánchez, T. Delgado Ballestero, B. Solano Vila, J. García-Caldentey, A. Rodríguez-Sanz, H. Brigas, D. Martins, J. Blanco Ameijeiras, M. Rodríguez-de Miguel (Madrid, Spain)

    Objective: The REONPARK study aims to evaluate COMT inhibitors (COMTi) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s disease (PD)…
  • 2025 International Congress

    Combining Machine Learning and Linear Mixed Models to Estimate Medication Effect in People with Parkinson’s Disease

    A. Castro Mejia, S. Sapienza, L. Pavelka, R. Kruger, J. Klucken (Belvaux, Luxembourg)

    Objective: To estimate medication effect, as the score difference between MDS-UPDRS III in OFF and ON-state, using a minimal set of clinical features. Background: The…
  • « Previous Page
  • 1
  • …
  • 92
  • 93
  • 94
  • 95
  • 96
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley